Polypeptide composition for evaluating immune state of hematopoietic stem cell transplantation patient after CMV infection and detection kit

Abstract

The invention provides a polypeptide composition for evaluating the immune state of a hematopoietic stem cell transplantation patient after CMV infection. The composition comprises amino acid sequences as shown in SEQ ID NO: 1-383. The invention also provides a detection kit which comprises the following reagents: a reagent 1, a reagent 2, a reagent 3, a reagent 4, a reagent 7 and a reagent 8, wherein the reagent 1 contains the polypeptide composition disclosed by the invention. The kit covers main CMV T cell epitopes, so that the method for evaluating the immune state of the hematopoietic stem cell transplantation patient after CMV infection by taking CMV specific CTL as a predictive index is more sensitive in diagnosis, high in coverage rate and not limited by HLA subtypes.

Description

technical field [0001] The invention belongs to the technical field of medical detection, and in particular relates to a polypeptide composition and a detection kit for evaluating the immune status of hematopoietic stem cell transplantation patients after CMV infection. Background technique [0002] Currently, methods for assessing the immune status of cytomegalovirus (CMV) infection in patients after hematopoietic stem cell transplantation include the following: 1) Based on high-throughput sequencing, T cell immune repertoire is detected simultaneously, and TCR variable is calculated. The number of regions was used to quantify T cell diversity and thus evaluate cellular immunity. 2) Simply analyze the number of CD4+ T cells in human peripheral blood to evaluate the patient's immune reconstitution. 3) Evaluate the patient's immune status by detecting the content of antigen CMV-pp65, antibody CMV-IgG and CMV-IgM or viral nucleic acid CMV-DNA in serum. [0003] However, the ...

AI Technical Summary

Problems solved by technology

[0003] However, the above method has the following disadvantages: 1) T cell immune repertoire needs to be measured, which is time-consuming, laborious and expensive

3) The detection of serum CMV-IgG and IgM is basically aimed at past infections, and false negatives are prone to occur in the immunosuppressed state, causing patients to miss the best opportunity for treatment; CMV-DNA detection is widely used at this stage, and the positive threshold standard can not distinguish One (500copies / mL, 1000copies / mL), and a negative test does not necessarily mean that there is no virus replication in the patient, and a positive test does not necessarily mean that it is a live virus; the applicability of CMV-pp65 antigen detection is also very limited, and ELISA detection has high specificity. But the sensitivity is low, and the detection rate is lower than that of DNA detection

[0005] Although virus-specific cytotoxic T lymphocytes (cytotoxic lymphocytes, CTLs) have shown great advantages in the diagnosis and treatment of CMV diseases, there are still certain technical bottlenecks in this method, mainly in the presence of different human lymphocyte antigens (human lymphocyte antigens). , HLA) background patients’ CMV antigen-specific CD8+ T cells target a variety of antigens, therefore, how to accurately evaluate their cellular immunity (including the state of cellular immunity against CMV) against CMV-infected patients with different HLA backgrounds Technical problems to be solved in this field

Images